QuidelOrtho Corporation logo

QuidelOrtho Corporation

QDEL

NASDAQHealthcareMedical - Specialties

Previous close

$14.74

−$0.11 · -0.74%

Aug 21, 4:00 PM ET

QDEL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

43

Neutral

Sentiment

55

Mixed

Risk resilience

38

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
US
CEO
Brian J. Blaser
Listed since
Feb 1, 1991
Employees
6,500

Market position

Day range

Current $14.74

52-week range

Current $14.74

Open
$14.965
Previous close
$14.85
Volume
2.02M
1× average
Average volume
2.02M
Average daily volume
Market cap
1.01B USD
Beta
0.69
Market reference 1
50-day average
$15.75
-6.41% below average
200-day average
$19.8511
-25.75% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.65B USD
EV / EBITDA
-9.53×
Earnings yield
-56.97%
Free cash flow yield
-4.18%

Profitability & efficiency

Return on equity
-58.93%
Return on assets
-19.62%
Return on invested capital
-18.34%

Financial health

Current ratio
1.5×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends90%31%-29%-89%Gross margin, FY2021: 75.26%Gross margin, FY2022: 59.28%Gross margin, FY2023: 49.94%Gross margin, FY2024: 46.23%Gross margin, FY2025: 46.67%Operating margin, FY2021: 53.34%Operating margin, FY2022: 25.83%Operating margin, FY2023: 4.64%Operating margin, FY2024: -70.46%Operating margin, FY2025: -33.67%Net margin, FY2021: 41.46%Net margin, FY2022: 16.80%Net margin, FY2023: -0.34%Net margin, FY2024: -73.74%Net margin, FY2025: -41.45%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 75.26%. Gross margin FY2022 59.28%. Gross margin FY2023 49.94%. Gross margin FY2024 46.23%. Gross margin FY2025 46.67%. Operating margin FY2021 53.34%. Operating margin FY2022 25.83%. Operating margin FY2023 4.64%. Operating margin FY2024 -70.46%. Operating margin FY2025 -33.67%. Net margin FY2021 41.46%. Net margin FY2022 16.80%. Net margin FY2023 -0.34%. Net margin FY2024 -73.74%. Net margin FY2025 -41.45%.

Income trends

Revenue

2.73B USD-1.89%

Operating income

−919.2M USD+53.12%

Net income

−1.13B USD+44.84%
Income trends across reported periods3.8B USD1.67B USD−456.6M USD−2.58B USDRevenue, FY2021: 1.7B USDRevenue, FY2022: 3.27B USDRevenue, FY2023: 3B USDRevenue, FY2024: 2.78B USDRevenue, FY2025: 2.73B USDOperating income, FY2021: 906M USDOperating income, FY2022: 843.7M USDOperating income, FY2023: 139.1M USDOperating income, FY2024: −1.96B USDOperating income, FY2025: −919.2M USDNet income, FY2021: 704.2M USDNet income, FY2022: 548.7M USDNet income, FY2023: −10.1M USDNet income, FY2024: −2.05B USDNet income, FY2025: −1.13B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.7B USD. Revenue FY2022 3.27B USD. Revenue FY2023 3B USD. Revenue FY2024 2.78B USD. Revenue FY2025 2.73B USD. Operating income FY2021 906M USD. Operating income FY2022 843.7M USD. Operating income FY2023 139.1M USD. Operating income FY2024 −1.96B USD. Operating income FY2025 −919.2M USD. Net income FY2021 704.2M USD. Net income FY2022 548.7M USD. Net income FY2023 −10.1M USD. Net income FY2024 −2.05B USD. Net income FY2025 −1.13B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.73B USD2.78B USD3B USD3.27B USD1.7B USD
Cost of goods sold1.46B USD1.5B USD1.5B USD1.33B USD420.3M USD
Gross profit1.27B USD1.29B USD1.5B USD1.94B USD1.28B USD
Research and development186.2M USD218.7M USD246.8M USD187.9M USD95.7M USD
Selling, general, and administrative746.3M USD766.8M USD763.2M USD621M USD239.6M USD
Operating expenses2.19B USD3.25B USD1.36B USD1.09B USD372.3M USD
Interest income2.2M USD1.3M USD300K USD
Interest expense177.6M USD188.3M USD178.9M USD74.5M USD700K USD
Depreciation and amortization442M USD453.4M USD457.2M USD283.6M USD52.7M USD
Operating income−919.2M USD−1.96B USD139.1M USD843.7M USD906M USD
Net income−1.13B USD−2.05B USD−10.1M USD548.7M USD704.2M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

8 institutions
Craig-HallumdowngradeBuyHold
William BlairdowngradeOutperformMarket Perform

QDEL news

QDEL peers

ETFs holding QDEL

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research QDEL

research.disclaimer